Zhao Yi, Jiang Cuiping, He Jianhua, Guo Qing, Lu Jing, Yang Yun, Zhang Wenli, Liu Jianping
Department of Pharmaceutics, China Pharmaceutical University , Nanjing 210009, PR China.
Bioconjug Chem. 2017 Feb 15;28(2):438-448. doi: 10.1021/acs.bioconjchem.6b00600. Epub 2017 Jan 5.
An atorvastatin calcium (AT)-loaded dextran sulfate (DXS)-coated core-shell reconstituted high density lipoprotein (rHDL), termed AT-DXS-LP-rHDL, was developed for targeted drug delivery to macrophages and suppression of inflammation via the high affinity of DXS with scavenge receptor class AI (SR-AI) as well as depletion of intracellular cholesterol by apolipoprotein A-I (apoA-I)-mediated cholesterol efflux. These core-shell nanoparticles comprising an AT-loaded negatively charged poly(lactide-co-glycolide) (PLGA) core and a cationic lipid bilayer shell were prepared by nanoprecipitation method followed by thin film hydration and extrusion. The nanoparticles were further functionalized with apoA-I and DXS via sodium cholate mediation and electrostatic interaction, respectively. The core-shell structure and the surface coating of apoA-I and DXS were verified by the increased particle size, inverted zeta potential, and reduced in vitro drug release rate. The TEM image further confirmed the entrapment of the PLGA nanoparticles in the aqueous interior of the liposomes. In vitro cell viability assay showed the biocompatibility of the AT-loaded nanocarriers. The cellular uptake study illustrated that the targeting efficacy to macrophages increased in the following order: PLGA nanoparticles (P-NP), core-shell nanoparticles (LP-NP), core-shell rHDL (LP-rHDL), and DXS-LP-rHDL. Moreover, cellular drug efficacy of AT-loaded nanoparticles in preventing macrophage-derived foam cell formation and inflammation such as intracellular lipid deposition, cholesterol esters content, DiI-oxLDL uptake, cholesterol efflux, and secretion of TNF-α, IL-6, and IL-10 was much better than that of the drug-free nanoparticles, consistent with the results of cellular uptake study. Collectively, AT-DXS-LP-rHDL, as multifunctional carriers, could not only deliver more drug to macrophages, but also present antiatherogenic actions of the biofunctional nanocarriers through damping oxidized low density lipoproteins (oxLDL) uptake and promoting cholesterol efflux.
开发了一种载有阿托伐他汀钙(AT)的硫酸葡聚糖(DXS)包被的核壳型重组高密度脂蛋白(rHDL),称为AT-DXS-LP-rHDL,用于通过DXS与A类清道夫受体(SR-AI)的高亲和力以及载脂蛋白A-I(apoA-I)介导的胆固醇外流来消耗细胞内胆固醇,从而将药物靶向递送至巨噬细胞并抑制炎症。这些核壳纳米颗粒由负载AT的带负电荷的聚(丙交酯-共-乙交酯)(PLGA)核和阳离子脂质双层壳组成,通过纳米沉淀法制备,随后进行薄膜水化和挤压。纳米颗粒分别通过胆酸钠介导和静电相互作用用apoA-I和DXS进一步功能化。核壳结构以及apoA-I和DXS的表面包被通过粒径增加、zeta电位反转和体外药物释放速率降低得到证实。透射电镜图像进一步证实了PLGA纳米颗粒被包裹在脂质体的水性内部。体外细胞活力测定显示了载有AT的纳米载体的生物相容性。细胞摄取研究表明,对巨噬细胞的靶向效力按以下顺序增加:PLGA纳米颗粒(P-NP)、核壳纳米颗粒(LP-NP)、核壳rHDL(LP-rHDL)和DXS-LP-rHDL。此外,载有AT的纳米颗粒在预防巨噬细胞衍生的泡沫细胞形成和炎症方面的细胞药物效力,如细胞内脂质沉积、胆固醇酯含量、DiI-氧化低密度脂蛋白摄取、胆固醇外流以及肿瘤坏死因子-α、白细胞介素-6和白细胞介素-10的分泌,比无药物纳米颗粒要好得多,这与细胞摄取研究结果一致。总体而言,AT-DXS-LP-rHDL作为多功能载体,不仅可以向巨噬细胞递送更多药物,还可以通过抑制氧化低密度脂蛋白(oxLDL)摄取和促进胆固醇外流来呈现生物功能纳米载体的抗动脉粥样硬化作用。
Biochim Biophys Acta Mol Cell Biol Lipids. 2017-5-18
Exploration (Beijing). 2023-12-7
Basic Res Cardiol. 2024-2
Expert Opin Ther Targets. 2023